As the Centers for Medicare and Medicaid Services calls for public feedback on how to stop lab test fraud, experts say a tailored regulatory strategy will be key to avoid stifling innovation.
PHILADELPHIA--(BUSINESS WIRE)--Vivodyne, a biotech that discovers and develops more effective drugs by testing them on lab-grown human organs, today announced the close of $38 million in total seed ...
Spinal cord injuries cause permanent paralysis in part because inflammation, cell death, and glial scarring block nerve regeneration, and there has been no reliable human tissue model to test ...
Khosla Ventures-backed Vivodyne is growing human tissues in the lab to test potential new therapies before they go to clinical trials. Only about 10% of drugs in development ever make it to market.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results